In accordance with the findings of earlier studies, our study found no statistically significant differences between the high and low expression levels of CD3 and CD8 in either the training or validation groups in terms of patient age, gender, tumor size, or histological lung cancer staging (P > 0.05). The gene discussed is CD8A; the disease is lung cancer.